STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
BALANCE at Sep. 30, 2017	$ 119,031	$ 296,298,401	$ (299,754,409)	$ (3,336,977)
BALANCE, Shares at Sep. 30, 2017	11,903,133
Sale of common stock	$ 76,906	11,715,335		11,792,241
Sale of common stock, Shares	7,690,623
Warrant exercises	$ 40,721	10,752,142		10,792,863
Warrant exercises, shares	4,072,109
Warrants issued with notes payable		947,616		947,616
401(k) contributions paid in common stock	$ 937	144,153		145,090
401(k) contributions paid in common stock, Shares	93,640
Conversion of notes payable to common stock	$ 11,950	2,363,066		2,375,016
Conversion of notes payable to common stock, Shares	1,194,930
Stock issued to nonemployees for service	$ 3,562	689,626		693,188
Stock issued to nonemployees for service, Shares	356,197
Shares issued for settlement of clinical research costs	$ 22,600	5,484,800		5,507,400
Shares issued for settlement of clinical research costs, shares	2,260,000
Equity based compensation - employees		2,743,267		2,743,267
Purchase of stock by officers and directors	$ 4,639	380,361		385,000
Purchase of stock by officers and directors	463,855
Stock issuance cost		(206,583)		(206,583)
Net loss			(31,837,205)	(31,837,205)
BALANCE at Sep. 30, 2018	$ 280,346	331,312,184	(331,591,614)	916
BALANCE, Shares at Sep. 30, 2018	28,034,487
Warrant exercises	$ 66,775	18,039,842		18,106,617
Warrant exercises, shares	6,677,519
401(k) contributions paid in common stock	$ 310	143,568		143,878
401(k) contributions paid in common stock, Shares	30,996
Stock issued to nonemployees for service	$ 1,999	876,589		878,588
Stock issued to nonemployees for service, Shares	199,977
Shares issued for settlement of clinical research costs	$ 1,851	3,398,149		3,400,000
Shares issued for settlement of clinical research costs, shares	185,095
Equity based compensation - employees	$ (75)	4,428,249		4,428,174
Equity based compensation - employees, Shares	(7,500)
Option exercises	$ 660	149,822		150,482
Option exercises, Shares	65,997
Purchase of stock by officers and directors	$ 452	291,545		291,997
Purchase of stock by officers and directors	45,205
Stock issuance cost		(132,345)		(132,345)
Net loss			(22,134,640)	(22,134,640)
BALANCE at Sep. 30, 2019	$ 352,318	$ 358,507,603	$ (353,726,254)	$ 5,133,667
BALANCE, Shares at Sep. 30, 2019	35,231,776